SynCore Biotechnology Co Ltd

SynCore Biotechnology maintains a strong liquidity position, with cash and equivalents amounting to TWD 157.33 million, representing 61.5% of total assets. The company's liquidity FPT (free cash flow to total assets) is negative at -11.1%, indicating ongoing cash outflows from operations. Despite this, the current ratio of 21.37 suggests a robust ability to cover short-term liabilities. Profitability metrics are negative, with a return on equity of -18.63% and a return on assets of -17.89%, both significantly below the industry median for biotechnology firms. The company reported a net loss of TWD 45.76 million in the latest period, with operating income at -TWD 47.20 million. Gross profit of TWD 21.09 million reflects a margin of 78.0%, which is high for a biotechnology firm but insufficient to offset R&D and operational costs. The company's revenue is concentrated in the domestic market, with no disclosed international revenue streams. This geographic concentration increases exposure to local regulatory and economic conditions. SynCore operates a single business segment focused on therapeutic drug development, with no diversification across product lines or geographies. Outlook for the current fiscal year shows a revenue decline, with a projected decrease of 12.3% year-over-year. The company is expected to continue incurring losses, with net income remaining negative. Capital expenditures are minimal at TWD 406,000, suggesting a focus on cash preservation rather than expansion. Risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The company has a low debt-to-equity ratio of 0.01, indicating a conservative capital structure. However, the negative operating cash flow of TWD -38.33 million raises concerns about long-term sustainability without significant revenue growth or cost reductions. Recent filings and transcripts do not disclose material events or strategic shifts. The company remains focused on clinical trials for SB01 and SB03, with no new product launches or partnerships announced in the latest reporting period.